SMS Pharmaceuticals Reports Strong FY24 Performance with 47% PAT Growth

Full-year PAT ₹102 crore; FY24 EBITDA Margin 11%

What Happened

SMS Pharmaceuticals Ltd. announced strong financial results for the fiscal year ending March 2024 (FY24). Consolidated profit after tax (PAT) grew by 47% year-on-year to ₹102 crore. This includes profits from the recent VKT Pharma acquisition. The company's revenue increased by 13%, largely due to its performance in Active Pharmaceutical Ingredients (APIs).

Furthermore, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margins improved by 267 basis points to reach 11% in FY24. The company proposed a final dividend of ₹0.40 per share. A significant capital expenditure program of ₹280 crore is underway to enhance manufacturing capabilities, with completion expected by FY25.

Why It Matters

The 47% PAT increase highlights SMS Pharmaceuticals' successful integration of VKT Pharma and the strength of its API business. Improved EBITDA margins indicate better operational efficiency and cost management. The ongoing capital expenditure signals a commitment to future growth and expanded capacity, which could further boost earnings.

Company Background

SMS Pharmaceuticals operates in the pharmaceutical sector, focusing on APIs and contract manufacturing. The company has been expanding its operations and product offerings. The acquisition of VKT Pharma was a key strategy to strengthen its market position and diversify revenue streams.

What's Next

With strong FY24 results, shareholders may benefit from the recommended dividend. The ₹280 crore capital expenditure program, slated for completion by FY25, points to future expansion. Successful completion of this expansion and backward integration projects could lead to continued margin improvement and revenue growth in the coming years.

Potential Risks

Investors should monitor the successful execution of the capital expenditure program and its impact on future margins. Any delays or cost overruns in the capital expenditure could affect performance. The company's reliance on the API segment also poses a risk if market conditions change unfavorably.

Key Metrics

• Full-year PAT FY24: ₹102 crore (up 47% year-over-year)
• FY24 EBITDA Margin: 11% (up 267 basis points year-over-year)
• FY24 Revenue Growth: 13%
• Capex Program: ₹280 crore, targeted completion by FY25
• Final Dividend: ₹0.40 (40%) per share

What to Track

Investors will be watching the progress and timely completion of the ₹280 crore capital expenditure program by FY25. The company's ability to leverage backward integration projects to further enhance profit margins will also be a key factor in upcoming financial results.